TrialA Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Trial details
- Registry ID
- NCT03762850
- Phase
- Phase 3
Drug research
Dapagliflozin
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyNCT03762850 | TVTX | Phase 3 | Active not recruiting | 2023-08-07Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |